|
Name |
Phe-Pro
|
| Molecular Formula | C14H18N2O3 | |
| IUPAC Name* |
(2S)-1-[(2S)-2-amino-3-phenylpropanoyl]pyrrolidine-2-carboxylic acid
|
|
| SMILES |
C1C[C@H](N(C1)C(=O)[C@H](CC2=CC=CC=C2)N)C(=O)O
|
|
| InChI |
InChI=1S/C14H18N2O3/c15-11(9-10-5-2-1-3-6-10)13(17)16-8-4-7-12(16)14(18)19/h1-3,5-6,11-12H,4,7-9,15H2,(H,18,19)/t11-,12-/m0/s1
|
|
| InChIKey |
WEQJQNWXCSUVMA-RYUDHWBXSA-N
|
|
| Synonyms |
Phe-Pro; 7669-65-0; L-phenylalanyl-L-proline; H-Phe-Pro-OH; (S)-1-((S)-2-Amino-3-phenylpropanoyl)pyrrolidine-2-carboxylic acid; Phenylalanylproline; CHEMBL1807686; CHEBI:74750; (2S)-1-[(2S)-2-amino-3-phenylpropanoyl]pyrrolidine-2-carboxylic acid; Phenylalanyl-proline; Phe-Pro-OH; L-Phe-L-Pro; Phe-L-Pro, L-; SCHEMBL3726264; (1R)-1-L-Phenylalanyl-L-proline; (1S)-1-L-Phenylalanyl-L-proline; FP; ZINC2392313; BDBM50348852; MFCD00020833; AKOS010419073; CS-W012480; HY-W011764; AS-72048; H-D-PHE-PRO-OH TRIFLUOROACETATE SALT; A865431; Q27144877; (S)-1-((S)-2-Amino-3-phenylpropanoyl)pyrrolidine-2-carboxylicacid
|
|
| CAS | 7669-65-0 | |
| PubChem CID | 7020642 | |
| ChEMBL ID | CHEMBL1807686 |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 262.3 | ALogp: | -1.4 |
| HBD: | 2 | HBA: | 4 |
| Rotatable Bonds: | 4 | Lipinski's rule of five: | Accepted |
| Polar Surface Area: | 83.6 | Aromatic Rings: | 2 |
| Heavy Atoms: | 19 | QED Weighted: | 0.849 |
| Caco-2 Permeability: | -5.902 | MDCK Permeability: | 0.00086530 |
| Pgp-inhibitor: | 0.002 | Pgp-substrate: | 0.005 |
| Human Intestinal Absorption (HIA): | 0.258 | 20% Bioavailability (F20%): | 0.003 |
| 30% Bioavailability (F30%): | 0.004 |
| Blood-Brain-Barrier Penetration (BBB): | 0.524 | Plasma Protein Binding (PPB): | 18.64% |
| Volume Distribution (VD): | 0.244 | Fu: | 76.24% |
| CYP1A2-inhibitor: | 0.026 | CYP1A2-substrate: | 0.051 |
| CYP2C19-inhibitor: | 0.051 | CYP2C19-substrate: | 0.106 |
| CYP2C9-inhibitor: | 0.01 | CYP2C9-substrate: | 0.265 |
| CYP2D6-inhibitor: | 0.048 | CYP2D6-substrate: | 0.268 |
| CYP3A4-inhibitor: | 0.015 | CYP3A4-substrate: | 0.085 |
| Clearance (CL): | 10.977 | Half-life (T1/2): | 0.843 |
| hERG Blockers: | 0.053 | Human Hepatotoxicity (H-HT): | 0.767 |
| Drug-inuced Liver Injury (DILI): | 0.182 | AMES Toxicity: | 0.005 |
| Rat Oral Acute Toxicity: | 0.06 | Maximum Recommended Daily Dose: | 0.05 |
| Skin Sensitization: | 0.127 | Carcinogencity: | 0.018 |
| Eye Corrosion: | 0.003 | Eye Irritation: | 0.019 |
| Respiratory Toxicity: | 0.143 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC002115 | ![]() |
0.617 | D0N5HJ | ![]() |
0.584 | ||
| ENC000918 | ![]() |
0.561 | D00SEB | ![]() |
0.542 | ||
| ENC000130 | ![]() |
0.536 | D0R1CR | ![]() |
0.536 | ||
| ENC000749 | ![]() |
0.508 | D07HGR | ![]() |
0.523 | ||
| ENC001093 | ![]() |
0.462 | D0X5SJ | ![]() |
0.512 | ||
| ENC000717 | ![]() |
0.446 | D0I0EG | ![]() |
0.452 | ||
| ENC001904 | ![]() |
0.425 | D0P2YU | ![]() |
0.434 | ||
| ENC001819 | ![]() |
0.410 | D06PSS | ![]() |
0.410 | ||
| ENC000054 | ![]() |
0.397 | D04GKO | ![]() |
0.408 | ||
| ENC002014 | ![]() |
0.394 | D0T3LF | ![]() |
0.397 | ||